Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tri-Cyclen Lo Clears FDA; Ortho-McNeil Patches Up Contraceptive Line

Executive Summary

Ortho-McNeil is ready to launch the second pillar in its contraceptive product line defense following the approval of Tri-Cyclen Lo (norgestimate/ethinyl estradiol) Aug. 22

You may also be interested in...



Ortho Oral Contraceptives May Add Folic Acid, New Patent Life

Johnson & Johnson is pursuing a novel strategy to revive its oral contraceptive line: development of a patent-protected combination with folic acid

Ortho Oral Contraceptives May Add Folic Acid, New Patent Life

Johnson & Johnson is pursuing a novel strategy to revive its oral contraceptive line: development of a patent-protected combination with folic acid

Watson “Authorized” Generic Tri-Cyclen Will Share Market With Barr

Watson will launch an "authorized" generic version of Ortho-McNeil'soral contraceptive Ortho Tri-Cyclen when Barr enters the market with its generic under an agreement between Watson and Ortho announced Oct. 28

Related Content

UsernamePublicRestriction

Register

PS040389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel